<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218084</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-032</org_study_id>
    <nct_id>NCT04218084</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease</brief_title>
  <acronym>HOPE Kids 2</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in&#xD;
      pediatric participants, aged ≥ 2 to &lt; 15 years old, with Sickle Cell Disease. The primary&#xD;
      objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound)&#xD;
      measurements in SCD participants in this age range.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in&#xD;
      pediatric participants, aged ≥ 2 to &lt; 15 years old, with Sickle Cell Disease. The study will&#xD;
      be conducted at approximately 50 international clinical sites, and will enroll approximately&#xD;
      224 participants. Participants will be randomized in a 1:1 ratio to receive voxelotor or&#xD;
      placebo. All participants younger than 12 years of age and randomized to voxelotor will&#xD;
      receive a dose based on their body weight, to provide exposure corresponding to the adult&#xD;
      dose of 1500 mg/day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind, Placebo-Controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>TCD Measurement</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change in time averaged maximum of the mean velocity (TAMMV) arterial cerebral blood flow, as measured by TCD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in TCD Flow Velocity</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to Abnormal TCD Flow Velocity</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
    <description>Incidence of conversion to abnormal TCD flow velocity (≥ 200 cm/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reversion to Normal TCD Flow Velocity</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
    <description>Incidence of reversion to normal TCD flow velocity (&lt;170 cm/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCD Flow Velocity Reduction</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
    <description>Proportion of participants with TCD flow velocity reduction ≥ 15 cm/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Change in Hemoglobin (Hb)</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Unconjugated Bilirubin</measure>
    <time_frame>24, 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent of Reticulocyte</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Absolute Reticulocyte</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lactate Dehydrogenase (LDH)</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Voxelotor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voxelotor 1500mg or equivalent daily as a tablet or as powder for oral suspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voxelotor</intervention_name>
    <description>Participants are randomized 1:1 to receive voxelotor or placebo.</description>
    <arm_group_label>Voxelotor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Matching placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants with Sickle Cell Anemia (SCA)&#xD;
&#xD;
          2. TCD time averaged maximum of the mean velocity (TAMMV) arterial cerebral blood flow ≥&#xD;
             170 to &lt; 200cm/sec during the Screening Period&#xD;
&#xD;
          3. Hb ≥ 5.5 and ≤ 10.5 g/dL during screening&#xD;
&#xD;
          4. For participants taking HU, the dose of HU (mg/kg) must be stable for at least 90 days&#xD;
             prior to signing the informed consent form (ICF) and/or assent form, and with no&#xD;
             anticipated need for dose adjustments (other than weight based) or for initiation of&#xD;
             HU for non-chronic use during the study, in the opinion of the Investigator&#xD;
&#xD;
          5. Written informed parental/guardian consent and participant assent (where applicable)&#xD;
             has been obtained per IRB/EC policy and requirements, consistent with ICH guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body weight &lt; 5kg at the screening visit&#xD;
&#xD;
          2. Hospitalization for VOC or acute chest syndrome (ACS) within the 14 days prior to&#xD;
             execution of informed consent/assent (see Section 7.2.5.1 for the definition of VOC).&#xD;
&#xD;
          3. More than 10 VOCs within the past 12 months that required hospitalization, emergency&#xD;
             room, or clinic visit&#xD;
&#xD;
          4. Stroke resulting in focal neurological deficit; previous silent infarcts are&#xD;
             permitted.&#xD;
&#xD;
          5. Known history or findings, including screening magnetic resonance imaging&#xD;
             (MRI)/magnetic imaging angiography (MRA) findings, suggestive of significant cerebral&#xD;
             vasculopathy (eg, moyamoya or significant vasculopathy)&#xD;
&#xD;
          6. History of seizure disorder (History of febrile seizures is permissible if there have&#xD;
             been no seizures within the 12 months prior to randomization).&#xD;
&#xD;
          7. Has been treated with erythropoietin or other hematopoietic growth factors within 28&#xD;
             days of signing informed consent/assent or if, in the opinion of the Investigator,&#xD;
             there is an anticipated need for such agents during the study&#xD;
&#xD;
          8. RBC transfusion therapy (also termed chronic, prophylactic, or preventative&#xD;
             transfusion) or has received an RBC transfusion or exchange transfusion for any reason&#xD;
             within 90 days of signing the informed consent/assent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margaret Tonda, PharmD</last_name>
    <phone>(650) 741-7761</phone>
    <email>mtonda@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenni Herber</last_name>
    <phone>(650) 826-2422</phone>
    <email>jherber@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine Dumas</last_name>
      <phone>205-638-9416</phone>
      <email>jdumas@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Howard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Jesus Carhuas</last_name>
      <phone>202-476-3578</phone>
      <email>ccarhuas@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah J Acado</last_name>
      <phone>305-243-2930</phone>
      <email>s.acado@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Ofelia Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta-Hughes Spalding</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn Reese</last_name>
      <phone>404-785-4012</phone>
      <email>Shawn.Reese@choa.org</email>
    </contact>
    <investigator>
      <last_name>Robert Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta- Scottish Rite/ EMORY</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Ladd</last_name>
      <phone>404-785-8863</phone>
      <email>stacy.ladd@choa.org</email>
    </contact>
    <investigator>
      <last_name>Robert Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kayla Jones</last_name>
      <phone>312-227-4824</phone>
      <email>KSJones@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Robert Liem, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Brook</last_name>
      <email>Brooke.Kelly@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Natasha Archer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Health Care d/b/a Children's Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali Kolste</last_name>
      <phone>612-813-7146</phone>
      <email>ali.kolste@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Derrick Goubeaux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Glenda Thomas, RN</last_name>
      <email>gthomas@umc.edu</email>
    </contact>
    <contact_backup>
      <phone>601-984-2708</phone>
    </contact_backup>
    <investigator>
      <last_name>Melissa McNaull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals &amp; Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Mehrhof</last_name>
      <phone>816-234-3460</phone>
      <email>amehrhof@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Nazia Tabassum Iqbal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Settle</last_name>
      <phone>314-362-9015</phone>
      <email>settlea@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Hulbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Sabrick</last_name>
      <phone>267-426-9338</phone>
      <email>SABRICKJ@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Helge Hartung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Martino</last_name>
      <phone>412-692-6467</phone>
      <email>angela.martino2@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Ramasubramanian Kalpatthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Alston</last_name>
      <phone>843-876-8652</phone>
      <email>alstonch@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Shayla Bergmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivia McGregor</last_name>
      <email>Olivia.McGregor@STJUDE.ORG</email>
    </contact>
    <investigator>
      <last_name>Jeremie Estepp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chukwuma Kalu</last_name>
      <phone>832-834-4659</phone>
      <email>cokalu@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Venee Tubman, MD, MSSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zagazig University Hospital</name>
      <address>
        <city>Zagazig</city>
        <state>Al Sharkeya</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Hanna</last_name>
      <phone>201096286333</phone>
      <email>menagerges2000@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed Badr, MD, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexandria University Hospital</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nouran Nasr Awad</last_name>
      <phone>+201273704221</phone>
      <email>dr.nourannasr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hoda Hassab, MBCHB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatma Ebeid</last_name>
      <phone>201095569596</phone>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Azza Tantawy, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abu El Rich Hospital, Cairo University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Magdy Nathan</last_name>
      <phone>201278761620</phone>
      <email>christine.magdy.maximos@pharma.asu.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Amal El-Beshlawy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Robert-Debré AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christelle Conde</last_name>
      <email>christelle.conde@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Holvoet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korle-Bu Teaching Hospital Child Health</name>
      <address>
        <city>Accra</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lyudmyla Korang</last_name>
      <phone>+233243407742</phone>
      <email>ludakorang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Catherine Segbefia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Komfo Anokye Teaching Hospital Research and Development Unit</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evans X Amuzu</last_name>
      <phone>+233243326598</phone>
      <email>evansxamuzu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vivian Paintsil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camilla Rosa</last_name>
      <phone>+39555662489</phone>
      <email>camilla.rosa@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Daniela Cuzzubbo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seconda Università degli Studi di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silverio Perrotta</last_name>
    </contact>
    <investigator>
      <last_name>Silverio Perrotta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Sorbara</last_name>
      <email>silvia.sorbara@aopd.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Raffaella Colombatti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CREATES - Strathmore University Medical Centre</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amina Salim</last_name>
      <phone>+254721945362</phone>
      <email>asalim@strathmore.edu</email>
    </contact>
    <investigator>
      <last_name>Bernhards Ogutu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gertrude's Children's Hospital</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercy Kamene Sammy</last_name>
      <phone>+254711264069</phone>
      <email>mkmunguti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jessie Githanga, MBChB, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KEMRI - Centre for Respiratory Disease Research (CRDR)</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Miera</last_name>
      <phone>(+254)724522474</phone>
      <email>moraajacqueline@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Videlis Nduba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nigeria Teaching Hospital</name>
      <address>
        <city>Enugu</city>
        <state>Enugu State</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ikechuwu Anigbogu</last_name>
      <phone>(+234)8037024183</phone>
      <email>ikechukwu.anigbogu@unn.edu.ng</email>
    </contact>
    <investigator>
      <last_name>Iheanyi Opkala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aminu Kano Teaching Hospital</name>
      <address>
        <city>Kano</city>
        <state>Kano State</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fahad Usman</last_name>
      <phone>8069370963</phone>
      <email>ufahd@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Shehu Abdullahi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeyemi Labaeka</last_name>
      <phone>8035768932</phone>
      <email>yemilabaeka2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Biobele Brown, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barau Dikko Teaching Hospital / Kaduna State University</name>
      <address>
        <city>Kaduna</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulrasheed Sani</last_name>
      <phone>8034709960</phone>
      <email>samalumfashi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Halima Bello-Manga, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lagos University Teaching Hospital</name>
      <address>
        <city>Lagos</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olubukola Omidiji</last_name>
      <phone>8122167403</phone>
      <email>olubukolaomidiji@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adeseye Akinsete, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sultan َQaboos University Hospital - Adults/Adolescents</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maryam Al Nabhani</last_name>
      <phone>+96893913538</phone>
      <email>1500a94@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Salam Al Kindi, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sultan َQaboos University Hospital - Pediatrics</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taimoora Subhi</last_name>
      <phone>+96896777825</phone>
      <email>Taimoora05@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yasser Wali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Abdullah Children's Specialist Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>14611</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khadijah Alqarni</last_name>
      <phone>0548918922</phone>
      <email>alqarnikh@ngha.med.sa</email>
    </contact>
    <investigator>
      <last_name>Mohamed Al Essa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Saud University</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marwa Alsatary</last_name>
      <phone>+966538423481</phone>
      <email>alsatarymarwa@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ali Al Shehri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Telfer, DM</last_name>
    </contact>
    <investigator>
      <last_name>Paul Telfer, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evelina Childrens Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Ndoro</last_name>
      <phone>+442071886637</phone>
      <email>sharon.ndoro@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Baba Inusa, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE5 9NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Subarna Chakravorty</last_name>
    </contact>
    <investigator>
      <last_name>Subarna Chakravorty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital - Dept of Haematology</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Lund</last_name>
      <email>k.lund@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Kirsten Lund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>France</country>
    <country>Ghana</country>
    <country>Italy</country>
    <country>Kenya</country>
    <country>Nigeria</country>
    <country>Oman</country>
    <country>Saudi Arabia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Transcranial Doppler Ultrasound (TCD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

